Aptinyx to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Aptinyx Inc. (Nasdaq: APTX) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference, where CEO Norbert Riedel will present virtually on January 14, 2021, at 9:10 a.m. Eastern Time. A live webcast will be available on the company's website, with an archive accessible for 30 days post-event. Aptinyx focuses on developing therapies for brain and nervous system disorders, utilizing a unique platform targeting NMDA receptors to enhance synaptic plasticity. The company has three clinical candidates including treatments for chronic pain and cognitive impairment.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will present virtually at the 39^th Annual J.P. Morgan Healthcare Conference. Norbert Riedel, Ph.D., chief executive officer, is scheduled to present on Thursday, January 14, 2021 at 9:10 a.m. Eastern Time.

A live webcast of the presentation will be available to view on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at https://ir.aptinyx.com and will be archived on Aptinyx’s website for 30 days following the event.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Source: Aptinyx Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201221005162/en/

FAQ

When is Aptinyx's presentation at the J.P. Morgan Healthcare Conference?

Aptinyx's presentation is on January 14, 2021, at 9:10 a.m. Eastern Time.

Where can I watch the Aptinyx presentation live?

You can watch the live presentation on the 'Events and Presentations' page of Aptinyx’s website.

What is the focus of Aptinyx's research?

Aptinyx focuses on developing treatments for brain and nervous system disorders using NMDA receptor modulators.

How many product candidates does Aptinyx have in clinical development?

Aptinyx has three product candidates in clinical development.

What types of conditions is Aptinyx seeking to treat?

Aptinyx is developing therapies for chronic pain, PTSD, and cognitive impairment associated with Parkinson's disease.